WHAT IS CLAIMED:

1. A combination of Compound A (mirdametinib), or a pharmaceutically acceptable salt form thereof, and Compound B (lifirafenib), or a pharmaceutically acceptable salt form thereof for use in treating a patient having a solid tumor, wherein compound A and compound B are each to be administered in a therapeutically effective amount.

2. The combination for the use of claim 1, wherein the therapeutically effective amount of Compound A is about 1 mg to about 5 mg per day; and/or the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 40 mg per day.

3. The combination for the use of claim 1, wherein:
   (i) a) the therapeutically effective amount of Compound A is about 1 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 15 mg per day, preferably about 20 mg per day;
   (ii) a) the therapeutically effective amount of Compound A is about 2 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 40 mg per day, optionally about 20 mg to about 35 mg per day, preferably about 20 mg per day, or about 15 mg per day;
   (iii) a) the therapeutically effective amount of Compound A is about 3 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg to about 40 mg per day, optionally about 20 mg to about 35 mg per day, preferably about 20 mg per day, or about 15 mg per day;
   (iv) a) the therapeutically effective amount of Compound A is about 4 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically

acceptable salt form thereof, is about 10 mg to about 40 mg per day, optionally about 20 mg to about 35 mg per day, preferably about 20 mg per day, about 15 mg per day, about 10 mg per day, or about 5 mg per day;

(v) a) the therapeutically effective amount of Compound A is about 5 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 10 mg to about 40 mg per day, optionally about 20 mg to about 40 mg per day;

(vi) a) the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 8 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg per day, or about 10 mg per day; or

(vii) a) the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 12 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 5 mg per day, or about 10 mg per day.

4. The combination for the use of any one of claims 1-3, wherein Compound B is a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

5. The combination for the use claim 4, wherein:

(i) a) the therapeutically effective amount of Compound A is about 1 mg per day and b) the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 5 mg to about 10 mg per day, preferably about 7 mg per day;

(ii) a) the therapeutically effective amount of Compound A is about 2 mg per day and b) the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 10 mg to about 30 mg per day, preferably about 13 mg per day, about 20 mg per day, or about 27 mg per day;

(iii) a) the therapeutically effective amount of Compound A is about 3 mg per day and b) the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 15 mg to about 40 mg per day, preferably about 20 mg per day, about 27 mg per day, or about 34 mg per day;

(iv) a) the therapeutically effective amount of Compound A is about 4 mg per day and b) the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg to about 40 mg per day, preferably about 27 mg per day, about 20 mg per day, about 13 mg per day, or about 7 mg per day;

(v) the therapeutically effective amount of Compound A is about 5 mg per day and the therapeutically effective amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 25 mg to about 40 mg per day, preferably about 34 mg per day;

(vi) a) the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 8 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 7 mg per day, or about 13 mg per day; or

(vii) a) the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, is about 12 mg per day and b) the therapeutically effective amount of Compound B, or a pharmaceutically acceptable salt form thereof, is about 7 mg per day or about 13 mg per day.

6. The combination for the use of any one of claims 1-5, wherein Compound A; and or Compound B is to be administered once per day.

7. The combination for the use of any one of claims 1-6, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are to be administered on a 28-day dosing cycle comprising:

I. (a) 21 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both to be administered; and (b) 7 days in which

neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered;

II. (a) 21 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof are both to be administered; followed by (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered;

III. (a) three 7-day periods each comprising (i) 5 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both to be administered and (ii) 2 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof are to be administered; and (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered;

IV. (a) three 7-day periods each comprising (i) 5 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both to be administered and (ii) 2 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered; followed by (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered;

V. (a) three 7-day periods each comprising (i) 4 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both to be administered and (ii) 3 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof are to be administered; and (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered; or

VI. (a) three 7-day periods each comprising (i) 4 days in which Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are both to be administered and (ii) 3 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered; followed by (b) 7 days in which neither Compound A nor Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered, optionally

wherein the 28-day dosing cycle is repeated up to a total of 24 consecutive 28-day dosing cycles.

8. The combination for the use of claim 6 or claim 7, wherein only Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered for a lead-in period prior to a first 28-day dosing cycle, optionally wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period is the same or lower than the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered during the first 28-day dosing cycle; and/or wherein the Compound B, or a pharmaceutically acceptable salt thereof, is to be administered daily during the lead-in period preferably once daily during the lead-in period.

9. The combination for the use of claim 6 or claim 7, wherein one or both of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered for a lead-in period prior to a first 28-day dosing cycle at a lower dose than the therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt form thereof, and Compound B, or a pharmaceutically acceptable salt thereof, to be administered during the first 28-day cycle.

10. The combination for the use of claim 9, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period is i) the same as the amount of Compound A, or a pharmaceutically acceptable salt thereof, to be administered during the first 28-day dosing cycle; or ii) lower than the amount of Compound A, or a pharmaceutically acceptable salt thereof, to be administered during the first 28-day dosing cycle.

11. The combination for the use of claim 9 or claim 10, wherein the amount of Compound A, or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period is about 1 mg to about 5 mg per day, optionally wherein the amount of Compound A,

or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period about 1 mg per day, about 2 mg per day, or about 3 mg per day.

12. The combination for the use of any one of claims 9-11, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period is i) the same as the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered during the first 28-day dosing cycle; or ii) lower than the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered during the first 28-day dosing cycle.

13. The combination for the use of any one of claims 9-11, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period is about 5 mg to about 25 mg per day, about 5 mg to about 20 mg per day, about 5 mg to about 15 mg per day.

14. The combination for the use of any one of claims 9-11, wherein the amount of Compound B, or a pharmaceutically acceptable salt thereof, to be administered in the lead-in period is about 5 mg per day, about 10 mg per day, about 15 mg per day, or about 20 mg per day.

15. The combination for the use of any one of claims 9-14, wherein the Compound B to be administered in the lead-in period is a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt.

16. The combination for the use of claim 15, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, to be administered in the lead-in period is about 5 mg to about 40 mg per day, about 5 mg to about 30 mg per day, or about 5 mg to about 25 mg per day.

17. The combination for the use of claim 15, wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, to be administered in the lead-in period is about 7 mg per day, about 13 mg per day, about 20 mg per day, or about 27 mg per day.

18. The combination for the use of any one of claims 9-17, wherein the lead-in period begins 21 days, 14 days, 10 days, or 7 days before the first 28-day dosing cycle.

19. The combination for the use of any one of claims 9-18, wherein the Compound A, or a pharmaceutically acceptable salt thereof, and Compound B, or a pharmaceutically acceptable salt thereof, are each to be administered daily during the lead-in period, preferably once daily during the lead-in period.

20. The combination for the use of any one of claims 1-19, wherein Compound A is provided in a pharmaceutically acceptable salt form; or in free base form.

21. A combination of Compound A (mirdametinib) and Compound B (lifirafenib), for use in treating a patient having a solid tumor, wherein the wherein the patient is to be to be administered once daily 2 mg Compound A as free base and 15 mg Compound B, or a pharmaceutically acceptable salt thereof.

22. The combination for the use of claim 21, wherein the Compound B is to be administered as a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt and, optionally wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 20 mg.

23. A combination of Compound A (mirdametinib) and Compound B (lifirafenib), for use in treating a patient having a solid tumor comprising, wherein the patient is to be to be administered once daily 2 mg Compound A as free base and 20 mg Compound B, or a pharmaceutically acceptable salt thereof.

24. A combination of Compound A (mirdametinib) and Compound B (lifirafenib) for use in treating a patient having a solid tumor, the treatment comprising a 7 day cycle that comprises:

I. (a) 3 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form to be administered once daily for 5 consecutive days; followed by (b) no Compound A or Compound B to be administered for 2 consecutive days; or

II. (a) 4 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form to be administered once daily for 5 consecutive days; followed by (b) no Compound A or Compound B to be administered for 2 consecutive days.

25. The combination for the use of claim 23 or claim 24 wherein the Compound B is to be administered as a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt and, optionally wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, is about 27 mg.

26. A combination of Compound A (mirdametinib) and Compound B (lifirafenib) for use in treating a patient having a solid tumor, the treatment comprising:

(a) a lead-in period that comprises 3 mg Compound A free base and 10 mg Compound B, or a pharmaceutically acceptable salt form thereof to be administered once daily, for 14 consecutive days; followed by

(b) a 7 day treatment cycle that comprises (i) 3 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore to be administered once daily, for 5 consecutive days; followed by (ii) no Compound A or Compound B for 2 consecutive days to be administered.

27. The combination for the use of claim 26, wherein the Compound B is to be administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt and, optionally wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, to be administered in the lead-in period is about 13 mg or about 27 mg.

28. A combination of Compound A (mirdametinib) and Compound B (lifirafenib) for use in treating a patient having a solid tumor, the treatment comprising:

I. (a) a lead-in period that comprises 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 1 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days;

II. (a) a lead-in period that comprises 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 2 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days;

III. (a) a lead-in period that comprises 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 3 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days; or

IV. (a) a lead-in period that comprises 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 4 mg of Compound A free base and 20 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days.

29. The combination for the use of claim 28, wherein the Compound B is to be administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt and, optionally wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, to be administered in the lead-in period is about 20 mg or about 27 mg.

30. A combination of Compound A (mirdametinib) and Compound B (lifirafenib) for use in treating a patient having a solid tumor, the treatment comprising:

I. (a) a lead-in period that comprises a total of 2 mg Compound A free base divided over two doses per day and 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 1 mg of Compound A free base twice daily and 15 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days;

II. (a) a lead-in period that comprises a total of 3 mg Compound A free base divided over two doses per day and 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily, for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 3 mg of Compound A free base and 15 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days; or

III. (a) a lead-in period that comprises a total of 4 mg Compound A free base divided over two doses per day and 15 mg Compound B, or a pharmaceutically acceptable salt form thereof, to be administered once daily for 14 consecutive days; followed by (b) a 7 day treatment cycle that comprises (i) 4 mg of Compound A free base and 15 mg of Compound B, or a pharmaceutically acceptable salt form therefore, to be administered once daily for 5 consecutive days; followed by (ii) no Compound A or Compound B to be administered for 2 consecutive days.

31. The combination for the use of claim 30, wherein the Compound B is to be administered in both the lead-in period and treatment cycle as a pharmaceutically acceptable salt form, preferably wherein the pharmaceutically acceptable salt form is a maleate salt, which can be a sesqui-maleate salt and, optionally wherein the amount of Compound B as a maleate salt, which can be a sesqui-maleate salt, to be administered in the lead-in period is about 13 mg, or about 20 mg.

32. A combination of Compound A (mirdametinib) and Compound B (lifirafenib) for use in treating a patient having a solid tumor, the treatment comprising:

(i) 2 mg Compound A as free base and once daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof to be administered twice daily;

(ii) 4 mg Compound A as free base and once daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof to be administered twice daily;

(iii) 6 mg Compound A as free base and once daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof to be administered twice daily;

(iv) 2 mg Compound A as free base and twice daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof to be administered twice daily;

(v) 4 mg Compound A as free base and twice daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof to be administered twice daily; or

(vi) 6 mg Compound A as free base and twice daily 5 mg Compound B, or a pharmaceutically acceptable salt thereof to be administered twice daily.

33. The combination of claim 32, wherein Compound B is a pharmaceutically acceptable salt form preferably wherein the pharmaceutically acceptable salt form is a maleate salt which can be a sesqui-maleate salt and, optionally wherein each dose of Compound B, as a maleate salt, which can be a sesqui-maleate salt, is about 7 mg.

34. The combination for the use of any one of claims 9-19 or 21-33, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, in the lead-in period and/or treatment period are to be administered in the same or different dosage forms.

35. The combination for the use of claim 34, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, in the lead-in period and/or treatment period are to be administered in the same dosage form and the dosage form is a capsule.

36. The combination for the use of any one of claims 34, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, in the lead-in period and/or treatment period are to be administered in different dosage forms, optionally wherein Compound A is to be administered before, concomitantly, or Compound B is to be administered subsequently, or a pharmaceutically acceptable salt form thereof.

37. The combination for the use of claim 36, wherein the dosage form of Compound A; and/or Compound B is a capsule.

38. The combination for the use of any one of claims 9-37, wherein Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, are to be administered orally.

39. A pharmaceutical composition comprising:
    a. Compound A;
    b. Compound B, or a pharmaceutically acceptable salt form thereof;
    c. a filler;

d. a disintegrant; and

e. a lubricant.

40. The pharmaceutical composition of claim 39, wherein:

(i) Compound A is present at about 0.8 mg to about 1.2 mg, or 1.5 mg to about 2.5 mg;

(ii) the pharmaceutically acceptable salt of Compound B is the maleic acid salt, which can be a sesqui-maleate salt, of Compound B and is present at about 6 mg to about 8 mg, or about 20 mg to about 35 mg;

(iii) the filler is present at about 80 wt/wt % to about 90 wt/wt %, or about 72.5 wt/wt % to about 85 wt/wt %;

(iv) the disintegrant is present at about 3.5 wt/wt % to about 4.5 wt/wt %; and/or

(v) the lubricant is present at about 1.5 wt/wt % to about 5.0 wt/wt %.

41. The pharmaceutical composition of claim 39 or claim 40, wherein the filler is selected from the group consisting of microcrystalline cellulose, lactose, mannitol, starch, dibasic calcium phosphate, and combinations thereof, preferably microcrystalline cellulose, further preferably wherein the microcrystalline cellulose is silicified microcrystalline cellulose.

42. The pharmaceutical composition of any one of claims 39-41, wherein the disintegrant is selected from the group consisting of croscarmellose, sodium starch glycolate, crospovidone, alginic acid, and combinations thereof, preferably croscarmellose sodium.

43. The pharmaceutical composition of any one of claims 39-42, wherein the lubricant is selected from the group consisting of sodium stearyl fumarate, magnesium stearate, glyceryl dibehenate, talc, or combinations thereof, preferably sodium stearyl fumarate or magnesium stearate.

44. The pharmaceutical composition of any one of claims 39-43, wherein the pharmaceutical composition is a tablet or capsule, preferably a capsule.

45. The pharmaceutical composition of claim 44, wherein the capsule comprises:

I. about 1.0 mg of Compound A and about 7 mg of the maleic acid salt of Compound B, which can be a sesqui-maleate salt, wherein each component of the capsule is as follows:

a. about 0.8 wt/wt % to about 1.2 wt/wt % of Compound A;
b. about 6 wt/wt % to about 8 wt/wt % of the maleic acid salt of Compound B, which can be a sesqui-maleate salt;
c. about 80 wt/wt % to about 90 wt/wt % of silicified microcrystalline cellulose;
d. about 3.5 wt/wt % to about 4.5 wt/wt % of croscarmellose sodium;
e. about 1.5 wt/wt % to about 5.0 wt/wt % of sodium stearyl fumarate; and
f. a gelatin capsule which encapsulates components a-e; or

II. about 2.0 mg of Compound A and about 27 mg of the maleic acid salt, which can be a sesqui-maleate salt, of Compound B, wherein each component of the capsule is as follows:

a. about 0.8 wt/wt % to about 1.3 wt/wt % of Compound A;
b. about 12.3 wt/wt % to about 15.0 wt/wt % of the maleic acid salt of Compound B, which can be a sesqui-maleate salt;
c. about 72.5 wt/wt % to about 85 wt/wt % of silicified microcrystalline cellulose;
d. about 3.5 wt/wt % to about 4.5 wt/wt % of croscarmellose sodium;
e. about 1.5 wt/wt % to about 5.0 wt/wt % of sodium stearyl fumarate; and
f. a gelatin capsule which encapsulates components a-e.

46. A pharmaceutical composition of any one of claims 39-45 for use in treating a patient having a solid tumor.

47. The combination for the use of any one of claims 1-38, or the pharmaceutical composition for the use of claim 46, wherein the solid tumor is selected from the group

consisting of malignant peripheral nerve sheath tumor, biliary tract cancer, breast cancer, cholangiocarcinoma, urothelial cancer, uterine neoplasm, lung adenocarcinoma, squamous non-small cell lung cancer, non-squamous non-small cell lung cancer, gastric cancer, sarcoma, bladder cancer, head and neck cancer, small cell lung cancer, endometrial cancer, esophageal cancer, adenoid cystic carcinoma, gallbladder cancer, colorectal cancer, thyroid cancer, hepatocellular cancer, prostate cancer, oral cancer, cervical cancer, pancreatic carcinoma, ovarian cancer, melanoma, and serous carcinoma to the peritoneum.

48. The combination for the use of any one of claims 1-38, or the pharmaceutical composition for the use of claim 46, wherein the patient has non-small cell lung cancer, endometrial cancer, ovarian cancer or low grade serous ovarian cancer.

49. The combination for the use of any one of claims 1-38, or the pharmaceutical composition for the use of claim 46, wherein the patient has a confirmed mutation in one or more of KRAS, NRAS, HRAS, BRAF, NF1, MEK1, and MEK2; and/or a confirmed mutation in RASA1 and/or RAF1.

50. The pharmaceutical composition for the use of any one of claims 46-49, wherein the pharmaceutical composition is to be administered on a 28-day dosing cycle comprising:

I. (a) 21 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof form, is to be administered; and (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered;

II. (a) 21 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered; followed by (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered;

III. (a) three 7-day periods each comprising (i) 5 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically

acceptable salt form thereof, is to be administered and (ii) 2 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered; and (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered;

IV. (a) three 7-day periods each comprising (i) 5 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered and (ii) 2 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered; followed by (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered;

V. (a) three 7-day periods each comprising (i) 4 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered and (ii) 3 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered; and (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered; or

VI (a) three 7-day periods each comprising (i) 4 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered and (ii) 3 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered; followed by (b) 7 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered, optionally

wherein the 28-day dosing cycle is repeated up to a total of 24 consecutive 28-day dosing cycles.

51. The pharmaceutical composition for the use of any one of claims 46-49, wherein the pharmaceutical composition is to be administered on a 7-day dosing cycle comprising (a) 5 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is to be administered; followed by (b) 2 days in which the pharmaceutical composition comprising Compound A and Compound B, or a pharmaceutically acceptable salt form thereof, is not to be administered.